Skip to content
DataLookout
Menu

NCT05743868

Metabolic Heterogeneity Underlying Hypertriglyceridemia: Hepatic Triglyceride Biosynthesis in Humans With Different Insulin Resistance Phenotypes

StatusTerminated
PhaseNot applicable
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 8 versions: 8 with changes below. See every version on ClinicalTrials.gov ↗

  1. Stopped Trial terminated Sponsor's reason: Poor accrual and lack of funding Show 5 more changesShow less
    • Eligibility criteria revised
    • Final enrollment: 8 participants (planned 40)
    • Primary and study completion dates changed from estimate of Jun 2026 to Jun 24, 2026
    • Secondary endpoints: details revised at 1 of 4 entries
    • Site details revised
  2. Minor Primary and study completion dates: Dec 2025 to Jun 2026v7
  3. Notable Primary and study completion dates: Jan 2025 to Dec 2025v6
  4. Minor Primary and study completion dates: Aug 2024 to Jan 2025
    • Collaborators revised (2)
    v5
  5. Minor Start date changed from estimate of Nov 2023 to Nov 16, 2023v4
Show 2 earlier versionsHide 2 earlier versions
  1. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date: Sep 2023 to Nov 2023
    • Site details revised
    v3
  2. Notable Start date: May 2023 to Sep 2023v2
  1. Study First Submitted
  • Stopped: terminated, suspended or withdrawn
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Effect of tissue-specific insulin resistance on contribution of DNL to plasma triglyceride
Timeframe: Baseline
Change in DNL in VLDL-triglycerides after a standard meal compared to a standard meal with premeal exercise.
Timeframe: study visit 1 and study visit 2, up to 8 weeks

Secondary (4)

Change in plasma triglycerides after a standard meal compared to a standard meal with premeal exercise
Baseline plasma triglycerides
Adipose insulin sensitivity
Skeletal muscle/whole-body insulin sensitivity assessed by oral glucose tolerance test (OGTT)

Arms and interventions

IR participants with standardized dinnerExperimental

Participants with global IR and tissue-specific IR. Participants with global IR (in both skeletal muscle and adipose tissue) and tissue-specific IR (in adipose tissue). Glucose tolerance, skeletal muscle/whole-body insulin sensitivity and adipose tissue insulin sensitivity will be evaluated prior to intervention. Contribution of DNL to hepatic VLDL will be measured using a deuterated water drink, to be ingested prior to the standardized dinner. Blood will be drawn the following morning for the measurement of deuterium incorporation into triglycerides. Plasma deuterium will be allowed to wash out over several weeks, and the 2nd deuterated water study will be performed.

IR participants with standardized dinner and premeal exerciseExperimental

Participants with global IR and tissue-specific IR. Participants with global IR (in both skeletal muscle and adipose tissue) and tissue-specific IR (in adipose tissue). Glucose tolerance, skeletal muscle/whole-body insulin sensitivity and adipose tissue insulin sensitivity will be evaluated prior to intervention. DNL will be assessed in all participants after a single day with short bouts of premeal exercise with a standardized dinner. Contribution of DNL to hepatic VLDL will be measured using a deuterated water drink, to be ingested prior to the standardized dinner. Blood will be drawn the following morning for the measurement of deuterium incorporation into triglycerides. Plasma deuterium will be allowed to wash out over several weeks, and the 2nd deuterated water study will be performed.

Behavioral: Standardized Dinner, Premeal exercise

Sites

1 site in 1 country

  • AMC AmsterdamAmsterdam, Netherlands